Urology - Surgery - Laboratories | Nagoya University GraduateSchool of Medicine

Laboratories

Back
Top > Laboratories > Surgery > Urology

SurgeryUrology

Introduction

The role of Nagoya University Hospital is clinical practice, research and education. The important role in the clinical medicine is development and practice of advanced medical technology and treatment, and creation of scientific evidence. In the research activity, our important mission is to conduct clinical studies to develop an advanced medical technology and provide useful scientific evidence, and to perform basic investigation, especially translational researches, the outcome of which leads to an innovation of clinical medicine. The department of Urology, Nagoya University Graduate School of Medicine practices a wide range of clinical medicine in the field of Urology and also conducting a basic investigation focusing on translational researches.
In our clinical practice, we perform (1) urological endoscopic surgery (laparoscopic surgery for urothelial cancer in the renal pelvis, ureter and bladder, prostate cancer, adrenal tumors; laparoscopic retroperitoneal lymph node dissection; endoscopic surgery for benign prostatic hyperplasia and urinary tract stones), (2) renal transplantation, (3) medical treatment for malignant tumors in the urinary tract (medical treatment of renal cell carcinoma with molecularly-targeted therapy and immune checkpoint inhibitor, chemotherapy or radiotherapy for urothelial cancer and testicular cancer, hormonal treatment/brachytherapy /IMRT/chemotherapy for prostate cancer), (4) robot-assisted surgery using the da Vinci surgical system such as prostatectomy for prostate cancer/partial nephrectomy for renal cell carcinoma/radical cystectomy for bladder cancer), (5) treatment of lower urinary tract dysfunction (benign prostatic hyperplasia, overactive bladder, neurogenic bladder, interstitial cystitis, etc), (6) implantation of artificial urethral sphincter, (7) reconstruction of the urinary tract (construction of neo-bladder, bladder augmentation, pyeloplasty, closure of vesico-vaginal fistula or uretero-vaginal fistula, etc), (8) treatment of the disorders in the field of female Urology (stress urinary incontinence, pelvic organ prolapse, etc), (9) regenerative treatment in Urology field, (10) urinary care for the elderly people (refer to the home page of Nagoya University Continence Information Center: www.med.nagoya-u.ac.jp/haisetsu/). We are also conducting clinical and basic researches in these fields.

Research Projects

1. Basic research for regeneration of the lower urinary tract using adipose-derived stem cells (ASCs)
i) Tissue engineering of the lower urinary tract using adipose-derived stem cells
 The lower urinary tract is regenerated by a Scaffold Free-Bio 3D printer using human adipose-derived mesenchymal stem cells (Adipose-derived Stem Cells; ASCs), which is low-serum cultured. We already constructed the urethra and successfully implanted it to a nude mouse.

project1_eng.jpg project2_eng.jpg

ii) Treatment of interstitial cystitis using ASCs with mannose
 We confirmed the improvement of bladder function, bladder pain, blood flow in the bladder and urothelial construction (by immunostaining and electron microscopic findings) in an interstitial cystitis model rat by intravesical instillation of human adipose-derived stem cells with mannose. We are continuing the research aiming at clinical application of this regenerative treatment modality.

project3_eng.jpg
Effect of intravesical instillation of ASC with MN

iii) Basic research for regeneration of urethral sphincter function using autologous adipose-derived stem cells
 Adipose-derived stem cells (ASCs) are injected to the periurethral space and external urethral sphincter to improve the urethral sphincteric function. By the injection of ASCs, we confirmed an increase of the urethral resistance. In addition, the injected ASCs differentiated into the smooth muscle and produced cytokines such as VEGF and HGF. Since the treatment of stress incontinence by the injection of ASCs would be indicated to the patients undergoing radical prostatectomy for prostate cancer, the effect of ASCs to the growth of prostate cancer cells was investigated. Co-culture of ASCs with prostate cancer cells demonstrated a decrease of PSA level in the medium. Subcutaneous transplantation of prostate cancer cells into a nude rat with ASCs decreased the size of the tumor. These results suggested that ASCs do not have promoting effect of prostate cancer cells.

project4.jpg project5.jpg
Periurethral injection of ASCs                  Immunostaining

iv) We are conducting other variety of researches for regenerative treatments, such as regeneration of the kidney using ASCs and treatment of lower urinary tract dysfunction using dental pulp-derived mesenchymal stem cells.

2. A first-in-man study of treatment of stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells (ADRCs)
 Approved by the Nagoya University Ethics Committee and the MHWL, we conducted a clinical study to treat stress urinary incontinence caused by the urethral sphincter deficiency by the periurethral injection of ADRCs. This was a first-in-man clinical study of regenerative treatment to treat the urethral sphincter deficiency using ADRCs. In the treatment of 14 male and 4 female patients, the amount of urine leakage decreased and one patient obtained complete continence. In addition, the blood flow in the injected area progressively increased and urethral function was also improved.

project6_eng.jpg project7.jpg
Peri-urethral Injection of Autologous ADRCs              Increase of blood flow at the injected area

3. Investigator-initiated multicenter clinical trial of periurethral injection of autologous ADRCs for stress urinary incontinence due to the urethral sphincter dysfunction caused by prostatectomy
 We started the investigator-initiated multicenter clinical trial for the periurethral injection of the autologous adipose-derived regenerative cells approved by the PMDA. Kanazawa, Shinshu and Dokkyo University participated in this clinical trial, with Nagoya University being the center institute. We aim at completing the clinical trial until 2018 and obtaining an approval by the MHWL and coverage by the national insurance.

project8_eng.jpg

4. Basic researches on lower urinary tract dysfunction
 In a variety of animal models of the lower urinary tract dysfunction such as prostatitis model rats, interstitial cystitis model rats and bladder outlet obstruction model rats, basic researches to investigate the new treatment modalities are conducted. In particular, experimental studies for a gene therapy using HSV vector concerning TRIPV1 and NGF are ongoing. The effect of bladder ischemia and oxidative stress on the lower urinary tract function, and treatment of these conditions are also the target of the investigation.

project10_eng.jpgproject11_eng.jpg
Effects of alpha-1 blocker, silodosin, in prostatitis model rats (inflammation, cytokine, blood flow, oxidative stress marker)

project12.jpg project13.jpg

5. Application of the multidisciplinary computational anatomy to predict the renal function before surgical intervention.
 We are trying to elucidate a renal compensation mechanism, to explore a prognostic factor of renal function and to establish a predictive model for renal function using the multidisciplinary computational anatomy. For example, by using this method, we could establish a surgical simulation model to minimize the postoperative renal function loss before the partial nephrectomy for renal cell carcinoma.

project14.jpg project15_eng.jpg

6. Elucidation of clinicopathological prognostic factor in prostate cancer.
 We found that intraductal carcinoma in the prostatic cancer tissue was a strong prognostic factor for the patients with prostate cancer in cooperative study with Prof. Tsuzuki of Department of Pathology, Aichi Medical school. We are further investigating the clinicopathological role of intra-ductal carcinoma in relationships with surgical treatment, hormonal therapy and chemotherapy.

project16.jpg
Intraductal carcinoma (prostate cancer)

7. Clinical studies for the treatment of the disorders in the Urological fields.
 A variety of clinical studies of high evidence level (the sample sizes > 200-300 patients) are conducted in Nagoya University Urological group. Our group also has a large number of surgery patients; radical prostatectomy for prostate cancer of >800 cases / year, nephrectomy for RCC of >300 cases / year, radical cystectomy for bladder cancer of >150 cases/year. We also operate on many patients in the urogynecological field such as pelvic organ prolapse and stress urinary incontinence (more than 500 cases / year) and conducting clinical studies.

Faculty Members

FacultyPositionDepartment
Masashi Kato Lecturer Urology
Yoshihisa Matsukawa Clinical lecturer Urology
Takash Fujita Assistant professor Urology
Yasuhito Funahashi Assistant professor Urology
Shohei Ishida Assistant professor Urology
Kazuna Matsuo Assistant clinical professor Urology
Kosuke Tochigi Assistant clinical professor Urology
Yushi Naito Assistant clinical professor Urology
Wataru Nakane Clinical fellow Urology
Tomoaki Muramatu Clinical fellow Urology
Aya Mori Clinical fellow Urology
Takuma Yuba Clinical fellow Urology
Yasuo Ito Clinical fellow Urology
Kazuaki Hanai Clinical fellow Urology
Akiyuki Asano Clinical fellow Urology

Bibliography

  • 2016
    1. Funahashi Y, Majima T, Matsukawa Y, Yamamoto T, Yoshida M, Gotoh M.Intraprostatic Reflux of Urine Induces Inflammation in a Rat. Prostate. 2016 Sep 29. doi: 10.1002/pros.23257. [Epub ahead of print] PubMed PMID: 27683251
    2. Matsukawa Y, Funahashi Y, Takai S, Majima T, Ogawa T, Narita H, Kato M, Gotoh M. Comparison of silodosin and naftopidil for efficacy in the treatment of benignprostatic enlargement complicated by overactive bladder: A randomized,prospective study (SNIPER study). J Urol. 2016 Sep 8. pii:S0022-5347(16)31211-3.doi: 10.1016/j.juro.2016.08.111. [Epub ahead of print] PubMed PMID: 27615436.
    3. Yokoyama O, Nishizawa O, Homma Y, Takeda M, Gotoh M, Kakizaki H, Akino H,Hayashi K, Yonemoto K. OASIS project group. Nocturnal polyuria and hypertensionin patients with lifestyle-related diseases and overactive bladder. J Urol. 2016 Aug 23. pii: S0022-5347(16)31080-1. doi: 10.1016/j.juro.2016.08.087. [Epub ahead of print] PubMed PMID: 27565397.
    4. Matsukawa Y, Funahashi Y, Takai S, Majima T, Ogawa T, Narita H, Kato M, Gotoh M. Comparison of silodosin and naftopidil for efficacy in the treatment of benignprostatic enlargement complicated by overactive bladder: A randomized,prospective study (SNIPER study). J Urol. 2016 Sep 8. pii:S0022-5347(16)31211-3.doi: 10.1016/j.juro.2016.08.111. [Epub ahead of print] PubMed PMID: 27615436.
    5. Funahashi Y, Kato M, Fujita T, Ishida S, Mori A, Gotoh M. Association Between the Polyomaviruses Titers and Decoy Cell Positivity Rates After RenalTransplantation. Transplant Proc., 2016;48:921-923.
    6. Nishio N, Fujimoto Y, Iwata Y, Takanari K, Kamei Y, Yamamoto T, Goto M. Autologous fat injection therapy including high concentration of adipose-derived regenerative cells in a vocal fold paralysis mode. J. laryntol. Otol., 2016; 8:1-9.
    7. Takahashi S, Takei M, Nishizawa O, Yamaguchi O, Kato K, Gotoh M, Yoshimura Y, Takeyama M, Ozawa H, Shimada M, Yamanishi T, Yoshida M, Tomoe H, Yokoyama O, Koyama M. Clinical Guideline for Female Lower Urinary Tract Symptoms. LUTS, 2016;8:5-29.
    8. Maki S, Itoh Y, Kubota S, Okada T, Nakahara R, Ito J, Kawamura M, Kamomae T, Naganawa S, Yoshino Y, Gotoh M, Ikeda M. Late rectal toxicity from image-guided intensity modulated radiotherapy for prostate cancer. Anticancer Research, 2016;36:2967-2974,
    9. Kato M, Tsuzuki T, Kimura K, Hirakawa A, Kinoshita F, Sassa N, Ishida R, Fukatsu A, Kimura T, Funahashi Y, Matsukawa Y, Hattori H, Gotoh M. The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation. Modern Pathology, 2016;29:166-173
    10. Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, Hirakawa A, Gotoh M. The change of testosterone secretion during the treatment of alpha-1 blocker in patients with benign prostatic hyperplasia. Urology, 2016; 88:149-54.
    11. Hirose Y, Yamaguchi M, Kawabata S, Murakami M, Nakashima M, Gotoh M, Yamamoto T. Effects of Extracellular pH on Dental Pulp Cells in vitro. J. Endod. Elsevier., 2016;42: 735-741.
    12. Hirose Y, Yamamoto T, Misako N, Funahashi Y, Matsukawa Y, Yamaguchi M, Kawabata S, Gotoh M. Injection of Dental Pulp Stem Cells Promotes Healing of Damaged Bladder Tissue in a Rat Model of Chemically Induced Cystitis. Cell Transplant., 2016;25 (3): 425-436.
  • 2015
    1. Gotoh M, Kobayashi T, Sogabe K: Characterization of symptom bother and health-related quality of life in 967 Japanese female patients with overactive bladder. Neurourol. Urodyn,, 2015;34:730-735
    2. Funahash Y, Wang Z, O’Malley KJ, Tyagi P, DeFranco DB, Gingrich JR, Takahashi R, Majima T, Gotoh M, Yoshimura N.Influence of E. Coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. The Prostate, 2015;75:381-385
    3. Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K. Safety and efficacy of mirabegron as add-on therapy in patients with overactive bladder treated with solifenacin: a postmarketing, open-label study in Japan (MILAI study). BJU Int., 2015;116:612-622.
    4. Matsukawa Y, Takai S, Asai K, Kasugai S, Narita H, Komatsu T, Kashiwagi Y, Kato M, Yamamoto T, Gotoh M. A slow stream is pathophysiologically related to a poor response to α1-adrenoceptor therapy in the treatment of storage symptoms associated with benign prostatic hyperplasia. Urology. 2015;86:558-564.
    5. Funahashi Y, Murotani K, Yoshino Y, Sassa N, Ishida S, Gotoh M. The renal tumor morphological characteristics that affect surgical planning for laparoscopic or open partial nephrectomy. Nagoya J. Med. Sci., 2015;77:229-235.
    6. Matsukawa Y, Takai S, Funahashi Y, Yamamoto T, Gotoh M. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder. Urology, 2015;85:786-790.
    7. Majima T, Yamamoto T, Funahashi Y, Takai S, Matsukawa Y, Yoshida M, Gotoh M. Effect of Naftopidil on Bladder Microcirculation in a Rat Model of Bladder Outlet Obstruction. LUTS, 2015 epub on ahead.
    8. Majima T, FunahashiY, Takai S, Goins WF, Gotoh M, Tyagi P, Glorioso JC, Yoshimura N. Herpes Simplex Virus Vector-Mediated Gene Delivery of Poreless TRPV1 Channels Reduces Bladder Overactivity and Nociception in Rats. Human Gene therapy, 2015;26:734-742.
  • 2014
    1. Funahashi Y, Kato M, Yoshino Y, Fujita T, Sassa N, Gotoh M. Comparison of renal ischemic damage during laparoscopic partial nephrectomy with artery-vein and artery-only clamping. J Endourol., 2014;28:306-11.
    2. Funahashi Y, Sassa N, Inada-Inoue M, Ando Y, Matsukawa Y, Gotoh M. Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years. Aktuelle Urol., 2014;45:132-134.
    3. Funahashi Y, Yoshida M, Yamamoto T, Majima T, Takai S, Gotoh M. Intravesical Application of Rebamipide Promotes Urothelial Healing in a Rat Cystitis Model. J. Urol., 2014;192:1864-1870.
    4. Sassa N, Kato K, Abe S, Iwano S, Ito S, Ikeda M, Shimamoto K, Yamamoto S, Yamamoto T, Gotoh M, Naganawa S. Evaluation of 11C-choline PET/CT for primary diagnosis and staging of urothelial carcinoma of the upper urinary tract: a pilot study.Eur J. Nucl. Med. Mol. Imaging, 2014;41:2232-2241.
    5. Sassa N, Kato M, Funahashi M, Maeda M, Inoue S, Gotoh M. Efficacy of Pre-surgical Axitinib for Shrinkage of Inferior Vena Cava Thrombus in a Patient with Advanced Renal Cell Carcinoma. Jpn. J. Clin. Oncol., 2014;44:370-373.
    6. Hirose Y, Murakami M, Hayashi Y, Osako Y, Yamamoto T, Gotoh M, Nakashima M. Augmentation of regenerative potential of mesenchymal stem cells by granulocyte-colony stimulating factor (G-CSF) induced mobilization. J. Stem Cell Res. Transplant., 2014;1:1-10.
    7. Gotoh M, Kobayashi T, Sogabe K. Characterization of symptom bother and health-related quality of life in 967 Japanese female patients with overactive bladder. Neurourol. Urodyn., 2015;34:730-735.
    8. Gotoh M, Kobayashi T and Sogabe K: Impact of symptom improvement on patients’ bother and quality of life in femala patients with overactive bladder treated by solifenacin (SET-Q).Int J Urol,, 2014; 21:505-511.
    9. Mizuno H, Suzuki Y, Watanabe Y, Sokabe T, Yamamoto Y, Hattori R, Gotoh M, Tominaga M. Potential role of transient receptor potential (TRP) channels in bladder cancer cells. J. Physiol. Sci., 2014;64:305-314.
    10. Maeda M, Funahashi Y, Sassa N, Fujita T, Majima T, Gotoh M. Prediction of partial nephrectomy outcomes by using the diameter-axis-polar nephrostomy score. Int. J. Urol., 2014;21:442-446.
    11. Funahashi Y, Kato M, Fujita T, Takai S, Kimura Y, Gotoh M. Prevalence of polyomavirus positivity in urine after renal transplantation. Transplant Proc., 2014;46:564-566.
    12. Funahashi Y, Kato M, Fujita T, Tsuruta K, Inoue S, Gotoh M. Correlation between urine and serum BK virus levels after renal transplantation. Transplant Proc., 2014;46:567-569.
    13. Matsukawa Y, Gotoh M, Kato M, Funahashi Y, Narita M, Mitsui K. Effect of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study. Int. J. Urol. 2014;1:826-830.
    14. Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, Hirabayashi H, Yoshino Y, Hattori R, Gotoh M. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate, 2014;74:680-687.
    15. Funahashi Y, Yoshida M, Yamamoto T, Majima T, Takai S, Gotoh M. Intravesical application of rebamipide suppresses bladder inflammation in a rat cystitis model. J. Urol., 2014;191:1147-1152.
    16. Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Ikeda Y, Ohkawa S. Phase III, randomized, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.BJU Int., 2014;113:951-960.
    17. Funahashi Y, Kato M, Yoshino Y, Fujita T, Sassa N, Gotoh M. Comparison of renal ischemic damage during laparoscopic partial nephrectomy with artery-vein and artery-only clamping. J. Endourol., 2014;28(3):306-311.
    18. Funahashi Y, O’Malley KJ, Kawamorita N, Tyagi P, DeFranco DB, Takahashi R, Gotoh M, Wang Z, Yoshimura N: Upregulation of Androgen-Responsive Genes and Transforming Growth Factor-b1CascadeGenes in a Rat Model of Non-Bacterial Prostatic Inflammation. The Prostate, 2014;74:337-345.
  • 2013
    1. Hirakawa T, Suzuki S, Kato K, Gotoh M, Yoshikawa Y.Randomized controlled trial of pelvic floor muscle training with or without biofeedback for urinary incontinence. Int. Urogynecol J., 2013;24:1347-1354.
    2. Fukatsu A, Tsuzuki T, Sassa N, Nishikimi T, Kimura T, Majima T, Yoshino Y, Hattori R, Gotoh M. Growth Pattern, an Important Pathologic Prognostic Parameter for Clear Cell Renal Cell Carcinoma. Am. J. Clin. Pathol., 2013;140:500-505.
    3. Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study. J. Urol., 2013;189(1 Suppl):S117-121.
    4. Takeda M, Nishizawa O, Gotoh M, Yoshida M, Takahashi S, Masumori N. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite alpha-blocker treatment in patients with BPH: the ADDITION study. Urology, 2013;82(4):887-893.
    5. Gotoh M, Yamamoto T, Kato M, Majima T, Toriyama T, Kamei Y, Matsukawa Y, Hirakawa Y, Funahashi Y.Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose-derived regenerative cells: 1-year outcomes in 11 patients.Int. J. Urol.、2013;21:294-300.
    6. Funahashi Y, Oguchi T, Goins WF, Gotoh M, Tyagi P, Goss JR, Glorioso JC, Yoshimura N. Herpes simplex virus vector-mediated gene therapy of tumor necrosis factor alpha blockade for bladder overactivity and nociception in rats. J. Urol., 2013;189:366-373.
    7. Yamamoto T,Funahashi Y Mastukawa Y, Kato M,Yoshino Y,Gotoh M. Pretreatment of renal subcapsular administration of adipose tissue-derived stem cells ameliorate ischemia reperfusion-induced acute kidney injury. Hirosaki Med.J., 2013;64(Suppl.):S1ppl.
  • 2012
    1. Yamamoto T, Gotoh M, Kato M, Majima T, Toriyama K, Kamei Y, Iwaguro H, Matsukawa Y,Funahashi Y. Periurethral injection of autologous adipose-derived regenerative cells for the treatment of male stress urinary incontinence: report of 3 initial cases. Int. J. Urol., 2012; 19:652-659.
    2. Kato M, Hattori R, Kamihira O, Yamada S, Gotoh M. Correlation between treated hypertension in prepregnancy and transplanted kidney function deterioration during pregnancy even if within pregnancy permission criteria. Transplant Proc., 2012;44:635-637.
    3. Mizuno T, Ito K, Miyagawa Y, Kimura K, Suzuki Y, Mizuno M, Ito Y, Funahashi Y, Hattori R, Gotoh M, Noda Y, Yamada K. Renal impairment after laparoscopic radical nephrectomy affects hypoglycaemic therapy. J. Clin. Pharm. Ther., 2012;37:49-52.
    4. Gotoh M, Matsukawa Y, Funahashi Y, Kato M, Maseki Y, Narita H, Kamihira O, Hattori R. Correlations among lower urinary tract symptoms, bother, and quality of life in patients with benign prostatic hyperplasia and associated fluctuations with tamsulosin administration. LUTS, 2012;4:45-50.
  • 2011
    1. Gotoh M. Editorials, The mechanisms underlying alpha 1-adrenoceptor antagonists and modulation of bladder function: an emerging role for changes in perfusion. J. Urol., 2011;186:2154-2155.
    2. Yokoyama O, Yamaguchi O, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M, Yamada S. Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder: impact on sleep evaluated by bladder diary. J. Urol., 2011;186:170-174.
    3. Watanabe T, Maruyama S, Yamamoto T, Kamo I, Yasuda K, Saka Y, Ozaki T,Yuzawa Y, Matsuo S, Gotoh M. Increased urethral resistance by periurethral injection of low serum cultured adipose-derived mesenchymal stromal cells in rats. Int. J .Urol., 2011;18:659-666.
    4. Gotoh M, Homma Y, Yokoyama O, Nishizawa O. The responsiveness and minimal clinically important change of the Overactive Bladder Symptom Score (OABSS) Urology, 2011;78:768-773.
    5. Ogawa T, Hattori R, Yamamoto T, Gotoh M. Safe use of ultrasonically activated devices based on current studies. Expert Rev. Medi. Devices, 2011;8: 319-324.
    6. Gotoh M, Yokoyama O, Nishizawa O. Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial. Int. J. Urol., 2011;18:365-373.
    7. Funahashi Y, Hattori R, Matsukawa Y, Komatsu T, Sassa N, Gotoh M. Clinical efficacy of a loading dose of naftopidil for patients with benign prostatic hyperplasia. World J. Urol., 2011;29:225-231.
    8. Nishikimi T, Tsuzuki T, Fujita T, Sassa N, Fukatsu A, Katsuno S, Yoshino Y, Hattori R, Gotoh M. The post-operative pathological prognostic parameters of clear cell renal cell carcinoma in pT1a cases. Pathol. Int,, 2011;61:116-121.
    9. Sassa N, hattori R, Tsuzuki T, Watarai Y, Fukatsu A, Katsuno S, Nishikimi T, Fujita T, Gotoh M. Renal cell carcinomas in hemodialysis patients:does hemodyalysis duration influence pathological cell types and prognosis? Nephrol. Dial. Transplant., 2011;26:1677-1682.
    10. Funahashi Y, Hattori R, Matsukawa Y, Komatsu T, Sassa N, Gotoh M. Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia. World J. Urol., 2011;29:225-231.
    11. Yamaguchi O1, Kakizaki H, Homma Y, Takeda M, Nishizawa O, Gotoh M, Yokoyama O, Seki N, Yoshida M. ASSIST Study Group. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. Urology, 2011;78:126-33.
  • 2010
    1. Mizuno H, Yamamoto T, Okutsu H, Ohtake A, Kato M, Gotoh M. Effect of tamsulosin on bladder microcirculation in a rat ischemia-reperfusion model, evaluated by pencil lens charge-coupled device microscopy system. Urology, 2010;76(5) 1266e1-5.
    2. Matsukawa Y, Hattori R, Komatsu T, Funahashi Y, Sassa N, Gotoh M. De novo detrusor underactivity after laparoscopic radical prostatectomy. Int. J. Urol.,2010;17:643-648.
    3. Funahashi Y, Hattori R, Yamamoto T, Kamihira O, Sassa N, Gotoh M. The relationship between renal parenchymal volume and single kidney glomerular filtration rate before and after unilateral kidney. Urology,2010;77:1404-1408.
    4. Funahashi Y, Hattori R, Matsukawa Y, Yamamoto T, Gotoh M. Solitary fibrous tumor of the seminal vesicle. Aktuel Urol,2010;41:326-327.
    5. Fujita T, Hattori R, Kinukawa T, Yamada S, Kamihira O, Yoshino Y, Kato M, Gotoh M. Laparoscopic cytoreductive nephrectomy with cytokine therapy for metastatic renal cell carcinomas. Asian J. Endoscop. Surg., 2010;3:140-144.
    6. Kim JS, Hattori R, Yamamoto T, Yoshino Y, Gotoh M. How can we safely use ultrasonic laparoscopic coagulating shears? Int. J. Urol.,2010;17:377-381.
    7. Hagikura M, Murakumo Y, Hasegawa M, Gotoh M, Takahashi M. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathology Int.,2010;60:735-743.
    8. Homma Y, Araki I, Igawa Y, Ozono S, Gotoh M, Yamanishi T, Yokoyama O, Yoshida M. Clinical guideline for male lower urinary tract symptoms. Int. J. Urol., 2009;16:775-790.
    9. Fumahashi Y, Iwata S, Ito Y, Kojima S, Yoshikawa T, Hattori R, Gotoh M, Nishiyama Y, Kimura H. Multiplex real-yime PCR assay for quantifying BK polymavirus, JC polyomavirus and adenovirus DNA simultaneously. J. Clin. Microbiology, 2010;48: 825-830.
  • 2009
    1. Imamura T, Yamamoto T, ishizuka O, Gotoh M, Nishizawa O. The mocroenvironment of freeze-injured mouse urinary bladders enables successful tissue engineering. Tissue Engineering,2009;15:3367-3375.
    2. Kato K, Suzuki S, Yamamoto T, Furuhashi K, Suzuki K, Murase T, Gotoh M. Clinical pathway for tension-free vaginal mesh procedure: Evaluation in 300 patients with pelvic organ prolapsed. Int. J. Urol., 2009;16:314-317.
    3. Funahashi Y, Hattori R, Yamamoto T, Mizutani K, Yoshino Y, Sassa N, Gotoh M. Ewing's sarcome/promitivr neuroectodermal tumor of the kidney. Aktuell Urol, 2009;40:247-249.
    4. Gotoh M, Homma Y, Funahashi Y, Matsukawa Y, Kato M. Psychometric validation of the Japanese version of the Interrnational Consultation on Incontinence Questionnaire-short form. Int. J. Urol., 2009;16:303-306.
    5. Sassa N, Hattori R, Yamamoto T, Katoh M, Komatsu T, Matsukawa T, Funahashi Y, Gotoh M. Direct visualization of renal hemodynamics affected by carbondioxide induced pneumoperitoneum. Urology, 2009;73:311-315.
    6. Hattori R, Yoshino Y, Komatsu T, Matsukawa Y, Ono Y, Gotoh M. Pre laparoscopic complete excision of distal ureter with a bladder cuff for upper urinary urothelial carcinoma. World J. Urol., 2009;27:253-258.
    7. Funahashi Y, Hattori R, Yamamoto T, Kamihira O, Moriya Y, Gotoh M. Change in contralateral renal parenchymal volume one week after unilateral nephrectomy. Urology, 2009;74:708-712.
    8. Funahashi Y, Hattori R, Yamamoto T, Kamihira O, Kato K, Gotoh M. Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur. Urol., 2009;55:209-216.
    9. Matsukawa Y, Hattori R, Yoshikawa Y, Ono Y, Gotoh M. Urodynamic evaluation of vesicourethral function following laparoscopic radical prostatectomy: comparison with open radical prostatectomy. Int. J. Urol., 2009;16:393-396.
    10. Gotoh M, Matsukawa Y, Yoshikawa Y, Funahashi Y, Kato M, Hattori R. Impact of urinary incontinence on the psychological burden of family caregivers. Neurourol. Urodyn., 2009;28:492-496.
    11. Komatsu T, Gotoh M, Funahashi Y, Matsukawa Y, Sassa N, Kato K, Kato M, Hattori R. Efficacy of propiverine in improving dymptoms and quality of life in female patients with wet overactivee bladder. LUTS,2009;1:2000-2024.
    12. Homma Y, Gotoh M. Symptom severity and patient perceptions in overactive bladder: how are they related? BJU Int.,2009;104:968-972.
    13. Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R. Efficacy of silodosin in relieving benign prostatic obstruction: a prospective study based on pressure flow study. J. Urol.,2009;182:2831-2835.
    14. Matsukawa Y, Hattori R, Yoshikawa Y, Ono Y, Gotoh M. Laparoscopic versus open radical prostatectomy: urodynamic evaluation of vesicourethral function. Int. J. Urol.,2009;16:393-396.
    15. Hattori R.Kamihira O, Yoshuno Y, Tsuchiya F, Fujita T, Yamada S, Funahashi Y, Ono Y, Gotoh M. Laparoscopic radical nephrectomy for large renal cell carcinoma. J. Endourol.,2009;23:1523-1526.
  • 2008
    1. Anas CM, Hattori R, Morita Y, Matsukawa Y, Komatsu T, Yoshino Y, Maruyama S, Yuzawa Y, Matsuo S, Gotoh M. Efficacy of laparoscopic-assisted renal biopsy. Clinical Nephrology, 2008;70:203-209.
    2. Ozaki T, Anas C, Maruyama S, Yamamoto T, Yasuda K, Morita Y, Ito Y, Gotoh M, Yuzawa, Y, Matsuo S. Intrarenal administration of recombitant human soluble thrombomodulin ameliorates ischemic acute renal failure. Nephrol. Dial. Transpl.,2008;23:110-119.
    3. Tanaka T, Noiri T, Yamamoto Y, Sugaya T, Negishi K, Maeda R, Nakamura K, Portilla D, Gotoh M, Fujita T. Urinary human L-FABP is a potnetial biomarker to predict COX-inhibitor-induced renal injury. Nephron Exp. Nephrol.,2008;108:19-26.
    4. Funahashi Y, Hattori R, Kinukawa T, Kimura H, Nishiyama Y, Gotoh M. Conversion from microfenorate mofetile to mizoribine for patients with positive polyomavirus type BK in urine. Transplantation Proc., 2008;40:2268-2270.
    5. Funahashi Y, Hattori R, Kinukawa T, Kimura H, Nishiyama Y, Gotoh M. Conversion from mycophenolate mofetil to mizoribine for patients with positive polyomvirus type BK in urine. Transplantation Proceedings, 2008;40: 2268-2270.
    6. Nishizawa O, Ishizuka O, Okamura K, Gotoh M, Hasegawa T, Hirao Y. Guideline for management of urinary incontinence. Int. J. Urol., 2008;15:857-874.
    7. Homma Y, Yoshida M, Yamanishi T, Gotoh M. Core lower urinary tract symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int. J. Urol., 2008;15:816-820.
  • 2007
    1. Anas C, Ozaki T, Maruyama S, Yamamoto T, Gotoh M, Ono Y, Matsuo S: Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure. Int. J. Urol., 2007;14: 219-225.
    2. Kondo A, Kamihira O, Gotoh M, Ozawa H, Lee TY, Lin ATL, Kim ARK, Lin HH. Folic acid prevents neural tube defects: International comparison of awareness among obstetricians・ gynecologists and urologists. J. Obstet. Gynaecol. Res.,2007;33: 63-67.
    3. Tsuchiya F, Hattri R, Gotoh M, Yamamoto T, Yoshino Y, Matsukawa Y, Komatsu T, Ono Y. Laparoscopic radical nephrectomy for locally advanced renal cell carcinoma. Jpn. J. Endourol. ESWL,2007;20:89-94.
    4. Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int., 2007;100:579-587.
    5. Kim TS, Hattori R, Yoshino Y, Komatsu T, Matsukawa Y, Gotoh M, Ono Y. Laparoscopic partial nephrectomy in upper-pole apical renal tumor using gauze sling and flexible laparoscope. J. Endourol., 2007;21:879-882.
    6. Gotoh M. Quality of life assessment for patients with urinary incontinence. Nagoya J. Med. Sci., 2007;69:123-131.
    7. Yamaguchi O, Honda K, Nomiya M, Gotoh M. Defining overactive bladder as hypersensitivity. Neurourol. Urodyn., 2007;26:904-907.
    8. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, Kimura K, Fujita T, Kinukawa T, Taniguchi H, Nakamura K, Gotoh M, Shinozaki N, Ohshima S, Sugaya T. Renal L-type fatty acid-binding protein in acute ischemic injury. J. Am. Soc. Nephrol., 2007;18:2894-2902.

Research Keywords

urology、 regenerative treatment、 adipose-derived regenerative cell、 lower urinary tract dysfunction、 urinary incontinence、 renal cell carcinoma、 prostate cancer、 bladder cancer、 urothelial cancer、 urinary incontinence、 testicular tumor、 pelvic organ prolapse

Call for graduate students

 We welcome graduate students, who are interested in clinical, basic, or both researches, to our department.